The article drew on the health technology assessment reports of the UK and Canada to provide suggestions for the development of comprehensive clinical evaluation of drugs in China. The completed full health technology assessment reports published by the United Kingdom (UK) and Canada from January 1, 2015 to August 4, 2022 were retrieved from the international HTA database on the official website of International Network of Agencies for Health Technology Assessment (INATA). Microsoft excel was used to extract the dimension information such as safety, effectiveness, cost-effectiveness and other key information in the HTA report, and descriptive statistical analysis was performed. A total of 325 HTA reports were finally included. Effectiveness, cost-effectiveness, and safety accounted for the highest proportions of evaluation dimensions, which were 250 (77%), 233 (72%), and 195 (60%), respectively. In addition, 153 (47%) reports assessed other dimensions. Among the 103 drug-related HTA reports, effectiveness, safety and cost-effectiveness accounted for the highest proportions of evaluation dimensions, which were 89 (86%), 83 (81%) and 73 (71%), respectively. In addition, 30 (29%) drug-related HTA reports assessed other dimensions. In conclusion, the comprehensive clinical evaluation of drugs in China can learn from the following characteristics of HTA reports of the UK and Canada to further improve its working mechanism: clarify the questions that need to be addressed in the comprehensive clinical evaluation of drugs, rationally select the dimensions of comprehensive clinical evaluation of drugs, carrying out comprehensive clinical evaluation of drugs starting from literature review, cost-effectiveness evaluation usually requires the team to carry out the original research to complete, budget impact analysis is only carried out with clear evidence users and necessity, multi-criteria decision analysis may not be an essential part of the HTA report itself, a comprehensive clinical evaluation of a drug can only answer limited questions.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |